Publication Name	World Journal of Clinical Oncology
Manuscript ID	111983
Country	Nepal

Category	Hematology
Manuscript Type	Observational Study
Article Title	Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing
Manuscript Source	Unsolicited Manuscript
All Author List	Abdulkareem AlGarni, Nawaf Alanazi, Sarah AlMukhaylid, Sultan Alqahtani, Hassan Almasoudi, Yaqob Samir Taleb, Nada Alkhamis, Sameerah Shaheen, Abdulaziz Haji Siyal, Aamer Aleem, Rizwan Naeem, Masood A Shammas, Giuseppe Saglio, Deema Alroweilly, Asraf Hussain and Zafar Iqbal
Funding Agency and Grant Number
Corresponding Author	Asraf Hussain, MD, Department of Oncology, Chitwan Medical College, Bharatpur-10, Chitwan, Bharatpur 33915, Nepal. drasrafcardiology@gmail.com
Key Words	Blast crisis chronic myeloid leukemia precision therapy; Pan-cancer genomic stratification; Artificial intelligence-guided drug repurposing; Catalogue of Somatic Mutations in Cancer signature-driven oncology; Machine learning in leukemia treatment
Core Tip	This study integrates whole-exome sequencing, machine learning, and artificial intelligence-driven drug repurposing to stratify blast crisis chronic myeloid leukemia (BC-CML) into three molecular subtypes based on pan-cancer mutations and Catalogue of Somatic Mutations in Cancer signatures. By identifying cluster-specific therapies (e.g., polyadenosine-diphosphate-ribose polymerase, isocitrate dehydrogenase, and Janus kinase inhibitors), the framework enables precision oncology for BC-CML, offering a scalable model for real-time patient stratification and Food and Drug Administration/European Medicines Agency-approved drug repurposing in re-lapsed/refractory hematologic malignancies.
Citation	AlGarni A, Alanazi N, AlMukhaylid S, Alqahtani S, Almasoudi H, Samir Taleb Y, Alkhamis N, Shaheen S, Haji Siyal A, Aleem A, Naeem R, Shammas MA, Saglio G, Alroweilly D, Hussain A, Iqbal Z. Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing. World J Clin Oncol 2025; In press

Received	2025-07-16 05:09
Peer-Review Started	2025-07-16 05:10
To Make the First Decision
Return for Revision	2025-08-11 05:17
Revised	2025-08-13 19:54
Second Decision	2025-09-30 02:46
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-09-30 07:07
Articles in Press	2025-09-30 07:07
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com